# RPG Life Sciences share price today (RPG Life Sciences Ltd, NSE: RPGLIFE)

> RPG Life Sciences share price today: ₹2,598.50 at the NSE close on 4 November 2026, up 8.3% in a year. RPG Life Sciences (NSE: RPGLIFE) is worth ₹4,297 crore, trades at a P/E of 38.5 and has closed between ₹1,864.60 and ₹3,050.60 over the past 52 weeks. > RPG Life Sciences Ltd's share price has risen faster than its earnings: +8.3% in a year, against −37.1% for earnings per share. RPGLIFE · Pharma - Formulators · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹2,598.50 (+8.3% in a year)
- P/E: 38.5× (higher than 80% of the last 10 years)
- Revenue (Sep 2026): ₹193 Cr (+6.0% on a year ago)
- Profit (Sep 2026): ₹23.0 Cr (−37.8% on a year ago)
- Operating margin: 17.0% (−4.0 points on a year ago)
- ROCE: 26%, FY26
- ROIC: 28.3%, against a 12.0% cost of capital: +16.3 points

The main question: the share price moved +8.3% in a year while yearly earnings per share moved −37.1%. The difference came from the market paying a higher multiple. ## What is the RPG Life Sciences share price today? RPG Life Sciences Ltd's share price was ₹2,598.50 at the close on 4 November 2026. It has been rising for 20 weeks. That is 3.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,865 and ₹3,051, and at that close it sat 62% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 19 weeks in a row. Over the last 11 years the share price moved +938% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at RPG Life Sciences this quarter? 1. Indian funds and insurers (DIIs) raised their stake for 14 quarters in a row From 0.1% to 9.9% of the company by the September 2026 quarter. 3. Revenue up on a year earlier for 9 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹193 crore, +6% on a year earlier. Why: Revenue was higher because all three parts of the business grew. The domestic business sold more, the active ingredient business did better, and international sales grew again. Next results: check whether domestic sales get back to their earlier pace after the stock and supply issues. From the earnings call on 30 Oct 2026. ## What are RPG Life Sciences' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), RPG Life Sciences reported revenue of ₹193 crore, up 6.0% from ₹182 crore a year earlier, and a profit of ₹23.0 crore, down 37.8% from ₹37.0 crore. ### RPG Life Sciences results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹193 crore | ₹182 crore | +6.0% |
| Profit | ₹23.0 crore | ₹37.0 crore | −37.8% |
| Earnings per share | ₹14.08 | ₹22.28 | −36.8% |
| Operating margin | 17.0% | 21.0% | −4.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). RPG Life Sciences' management discussed these results on a call held on 30 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the RPG Life Sciences share price history? RPG Life Sciences closed at ₹2,598.50 on 4 November 2026, up 8.3% from ₹2,400.40 a year earlier (7 November 2025) and up 267.4% over five years. Its highest weekly close since March 2016 was ₹3,050.60 on 25 September 2026. ### RPG Life Sciences share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹2,575.70 | +0.9% |
| 1 month ago · 1 Oct 2026 | ₹2,930.70 | −11.3% |
| 6 months ago · 8 May 2026 | ₹2,463.10 | +5.5% |
| 1 year ago · 7 Nov 2025 | ₹2,400.40 | +8.3% |
| 3 years ago · 3 Nov 2023 | ₹1,489.75 | +74.4% |
| 5 years ago · 4 Nov 2021 | ₹707.20 | +267.4% |
| 10 years ago · 4 Nov 2016 | ₹451.20 | +475.9% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹250.35 | +937.9% |
| Highest weekly close since March 2016, also the 52-week high · 25 Sep 2026 | ₹3,050.60 | −14.8% |
| Lowest weekly close since March 2016 · 27 Mar 2020 | ₹165.35 | +1,471.5% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹1,864.60 | +39.4% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 4 November 2026.)

## What is the latest news on RPG Life Sciences? 4 Nov 2026: RPG Life Sciences closed at ₹2,598.50, up 0.9% on the week and down 11.3% on the month. 30 Oct 2026: RPG Life Sciences held its results call for July to September 2026. Management guided: Acquired API H2 revenue ₹25 crore to ₹30 crore at mid-20s operating margin in line with existing base. ### Earlier

- Results for July to September 2026: Revenue up 6.0% and profit down 37.8% on a year earlier. - 9 Jul 2026: ex-date for a dividend of ₹24 a share. ## What dividend does RPG Life Sciences pay? RPG Life Sciences paid ₹24 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.92% at the ₹2,598.50 close on 4 November 2026. The last was a dividend of ₹24 a share, ex-date 9 July 2026. ### RPG Life Sciences dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 9 Jul 2026 | ₹24 | Dividend | same day |
| 27 Jun 2025 | ₹24 | Dividend + Special | same day |
| 28 Jun 2024 | ₹16 | Dividend | same day |
| 21 Jul 2023 | ₹12 | Dividend | same day |
| 14 Jul 2022 | ₹9.60 | Dividend | 15 Jul 2022 |
| 13 Aug 2021 | ₹7.20 | Dividend | 17 Aug 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. RPG Life Sciences Ltd paid out 34% of its profit as dividends in FY26, and it paid a dividend in each of its last 12 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did RPG Life Sciences management say on the latest results call? On the call for July to September 2026, held on 30 October 2026, RPG Life Sciences' management guided: Acquired API H2 revenue ₹25 crore to ₹30 crore at mid-20s operating margin in line with existing base. > Ashok Nair, on the call for July to September 2026

### What management guided

- API organic double-digit with combined at least 30% yearly growth over 3 to 5 years to ₹300-350 crore by FY30 and ₹500 crore by FY32. - Domestic Formulations above 1.5 times market growth with Q3 rebound to prior momentum. - International Formulations double-digit growth from H2 on stronger order pipeline and tender execution. - Chile and Ethiopia tenders about ₹10 crore from FY29 plus UK CDMO about ₹8 crore from FY29. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/5179-30-Oct-2026.pdf). (From the call for July to September 2026, 30 October 2026.)

## What to watch in RPG Life Sciences' next results? When RPG Life Sciences reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Domestic reported growth rebounds to flagged pace in Q3 with normalized stock and resolved supply. - What to check (from the call)
- Domestic reported growth rebounds to flagged pace in Q3 with normalized stock and resolved supply. - Acquired API posts full-quarter contribution in Q3 versus flagged H2 range - integration ramp test. - Canada shipments commence on schedule with early share traction for first over-the-counter push - execution check. ## Which stock lists is RPG Life Sciences on? RPG Life Sciences is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 4297.709360562178](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is RPG Life Sciences profitable? RPG Life Sciences Ltd earned ₹23.0 Cr of net profit in the Sep 2026 quarter, −37.8% on the same quarter a year earlier. Full-year FY26 profit was ₹115 Cr. Over 10 years profit has grown 25.4% a year on average. That is 11.9% of the quarter's revenue. The same quarter a year earlier earned ₹37.0 Cr. For the full year, FY26 profit was ₹115 Cr (−37.2% on the year before). Why profit moved: revenue changed +6.0% on a year earlier and the margin moved −4.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −32.5% and revenue +12.4%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does RPG Life Sciences make, and is it growing? RPG Life Sciences Ltd reported ₹193 Cr of revenue in the Sep 2026 quarter, +6.0% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 9.8% a year on average. The last full year, FY26, came in at ₹708 Cr. The last four reported quarters add to ₹746 Cr. FY26 revenue was ₹708 Cr, +8.4% on the year before. Recent pace: the last four quarters grew +12.4% on average, against 9.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +11.8%, against +9.9% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −50.7%, against +23.1% a year (rolling over). ## How much of every ₹100 of sales does RPG Life Sciences keep? RPG Life Sciences Ltd's operating margin was 17.0% in the Sep 2026 quarter, 4.0 percentage points lower than the same quarter a year ago. Across 12 years it has been between 6.0% and 25.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −4.6 percentage points on the year while gross margin changed +0.3 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is RPG Life Sciences' profit turning into cash? Over the last 3 years, 59% of RPG Life Sciences Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹56.0 Cr of operating cash against ₹115 Cr of profit. After ₹53.0 Cr of spending on assets, ₹3.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 59% of profit came in as cash: the cash cycle got 15 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 15 days longer. The next section looks at where the cash is stuck. ## Where does RPG Life Sciences' cash go? RPG Life Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 99 days in FY26, up from 84 days in FY21. It spent ₹130 Cr on assets over the last 3 years. Customers take 60 days to pay, and stock sits for 179 days on average. At FY26 sales of ₹708 Cr, each day of that cycle ties up about ₹1.9 Cr, so roughly ₹192 Cr is tied up in the business at any time. FY26: customers took 60 days to pay and stock sat for 179 days, about 5.9 months of sales sitting as stock, for a full cycle of 99 days, longer than FY21's 84. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 179 days. Customers pay about 60 days after that. Suppliers are paid at 141 days. Together that makes the 99-day cycle. Spending on assets: ₹130 Cr over the last 3 years, against ₹59.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹23.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is RPG Life Sciences' P/E ratio, and how does it compare with its own history? RPG Life Sciences Ltd's P/E is 38.5×, near the high end of its own history: higher than 80% of past readings. Its usual P/E (the middle reading) is 30.1×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹64.02. Why the multiple is where it is: over the past year earnings per share moved −37.1% while the price moved +8.3%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +29.7% a year; about +17.9% a year came from earnings growth and about +11.8 percentage points from the multiple (the market paying more); over 10 years the price moved +19.1% a year; about +15.3% a year came from earnings growth and about +3.8 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the RPG Life Sciences business getting better or worse? RPG Life Sciences Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −50.7% in the latest quarter, against +207.1% at its best in 12 quarters, with ROCE falling at 23.7%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does RPG Life Sciences earn on its capital? RPG Life Sciences Ltd earned a ROCE of 26% in FY26. That is up from a low of 2% in FY15. Its return on capital used (ROIC) is 16.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 16.2% net margin and 0.89× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 16.2% net margin × 0.89× asset turnover × 1.31× leverage (assets divided by equity) ≈ 18.9% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 28.3% − 12.0% = +16.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 28.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 30.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does RPG Life Sciences have too much debt? RPG Life Sciences Ltd has total debt of ₹4.0 Cr against shareholder equity of ₹619 Cr as of Sep 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.00 in FY22 to 0.03 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the RPG Life Sciences shareholding pattern? Domestic institutions raised their stake in RPG Life Sciences Ltd by 4.5 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 9.9% of the company. Foreign institutions moved −0.5 points over the same period, to 0.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +4.5 points over 8 quarters, to 9.9%; Foreign institutions: −0.5 points over 8 quarters, to 0.9%; Promoters: +0.1 points over 8 quarters, to 73.0%. Why the owners changed: domestic institutions drove it (+4.5 points), with the other side taken by foreign institutions (−0.5 points). They raised their stake step by step. ## How far is RPG Life Sciences from balance-sheet trouble? For RPG Life Sciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does RPG Life Sciences rank in its industry? 43.1 out of 100, rank 30 of 44 in Pharma - Formulators, with 100% of the evidence available. RPG Life Sciences Ltd scores 43.1 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 30. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 8.4 + 16.2 + 10.6 + 7.9 = 43.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is RPG Life Sciences compared with? RPG Life Sciences ranks 30 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 43.1 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.0/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18 + 11 + 12.3 = 71.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.5/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.5 + 9.1 + 18.6 = 70.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.4 + 11.2 + 8.6 = 69.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 7.1 + 10.5 = 69 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 66.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 20.4 + 16.1 + 2 = 66.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 8. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Most evidence points up · 74% evidence 65.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 18.3/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 18.3 + 6.3 + 11.9 = 65.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.7 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.3 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 59.5 out of 100 Growth Capital Valuation Relative
16. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
17. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.0 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.9 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 47.9 out of 100 Growth Capital Valuation Relative
24. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.6 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 45.9 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. RPG Life Sciences Ltd this page RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.4/35 · Revenue 11.8% · Profit -50.7% · Operating margin change -4 points · 100% evidence Capital efficiency 16.2/25 · ROCE 25.7% · Operating margin 17% · 100% evidence Valuation 10.6/20 · P/E 38.2× · PEG 1.04 · 100% evidence Relative strength 7.9/20 · Lead over its industry -7.9% · Lead over NIFTY 500 14.5% · 1 year 7.1% · 100% evidence · 9 of 12 weeks ahead Exact sum: 8.4 + 16.2 + 10.6 + 7.9 = 43.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.4 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 40.7 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.4 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 33.6 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to RPG Life Sciences in size? RPG Life Sciences is the 29th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Suven Life Sciences, Bliss GVS Pharma and FDC. Just below it: Gufic BioSciences, Kwality Pharmaceuticals and Fredun Pharmaceuticals. ### Pharma - Formulators companies close in size

1. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) ₹7,314 crore
2. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) ₹6,888 crore
3. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) ₹6,138 crore
4. RPG Life Sciences Ltd ₹4,260 crore
5. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) ₹4,147 crore
6. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) ₹3,606 crore
7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) ₹2,341 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Keystone Realtors Ltd](https://www.sectoralpha.in/stocks/keystone-realtors-ltd) ₹4,270 crore · Realty - Construction & Contracting
2. [Rolex Rings Ltd](https://www.sectoralpha.in/stocks/rolex-rings-ltd) ₹4,264 crore · Bearings
3. RPG Life Sciences Ltd ₹4,260 crore
4. [Laxmi Organic Industries Ltd](https://www.sectoralpha.in/stocks/laxmi-organic-industries-ltd) ₹4,245 crore · Chemicals - Organic
5. [AvenuesAI Ltd](https://www.sectoralpha.in/stocks/avenuesai-ltd) ₹4,207 crore · IT - Software

## What else do people ask about RPG Life Sciences? ### What is RPG Life Sciences's share price today? RPG Life Sciences Ltd's share price is ₹2,598.50, +8.3% over the past year. The whole company is worth ₹4,297 Cr on the market. In the last 52 weeks it traded between ₹1,865 to ₹3,051; today it is 62% of the way up from the low, 3.2% above its 200-day average (as of 4 November 2026). ### What were RPG Life Sciences's latest quarterly results? RPG Life Sciences Ltd reported revenue of ₹193 Cr and net profit of ₹23.0 Cr for the Sep 2026 quarter. Revenue rose 6.0% and profit fell 37.8% compared with a year earlier. Earnings per share were ₹14.08. The operating margin was 17.0%, 4.0 percentage points lower than a year earlier (as of 4 November 2026). ### What is RPG Life Sciences's market cap? RPG Life Sciences Ltd's market capitalisation is ₹4,297 Cr at a share price of ₹2,598.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is RPG Life Sciences performing? RPG Life Sciences Ltd's share price has been rising for 20 weeks. In its latest quarter, revenue rose 6.0% and profit fell 37.8% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 19 weeks running (as of 4 November 2026). ### Will RPG Life Sciences's share price go up? This page does not forecast RPG Life Sciences Ltd's share price. What it shows instead: the share price is ₹2,598.50, and it has been rising for 20 weeks. Its P/E of 38.5× is higher than 80% of its own last 10 years (as of 4 November 2026). ### Does RPG Life Sciences have too much debt? No, RPG Life Sciences Ltd has little debt: its debt is 0.03× its equity, and its operating profit is 74 times its interest bill. FY26 borrowings were ₹20.0 Cr against equity of ₹605 Cr. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### Where is RPG Life Sciences in its business cycle? RPG Life Sciences Ltd's FY26 operating margin was 21.0%, against a 12-year range of 6.0% to 25.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 17.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the RPG Life Sciences story? The main question: the share price moved +8.3% in a year while yearly earnings per share moved −37.1%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is RPG Life Sciences a stock worth studying right now? What the numbers show: RPG Life Sciences Ltd's share price has risen faster than its earnings: +8.3% in a year, against −37.1% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a RPG Life Sciences share price forecast for 2026? What management itself guided: Acquired API H2 revenue ₹25 crore to ₹30 crore at mid-20s operating margin in line with existing base. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.